Nintx Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$10M
- Investors
-
10
Nintx General Information
Description
Developer of drugs from medicinal plants designed to translate complex biological interactions into therapies. The company offers plant-based natural products with the potential to serve as a platform to modulate human biological targets and the microbiome concomitantly, enabling patients to get affordable therapies for multifactorial diseases.
Contact Information
Website
www.nintx.com.brCorporate Office
- Avenue Nações Unidas, 18801
- Conj 809, Jd Dom Bosco
- Sao Paulo, 04757-025
- Brazil
Corporate Office
- Avenue Nações Unidas, 18801
- Conj 809, Jd Dom Bosco
- Sao Paulo, 04757-025
- Brazil
Nintx Timeline
Nintx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A) | 09-Dec-2024 | $10M | Completed | Clinical Trials - General | ||
| 3. Grant | 01-Aug-2024 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 04-Aug-2022 | $3M | $3M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nintx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nintx Patents
Nintx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222530-A1 | Dietary supplement or pharmaceutical composition, use, production process and packaging system | Pending | 22-Apr-2025 | ||
| US-20250218310-A1 | Digestive system simulator apparatus and process | Pending | 27-Dec-2023 | ||
| WO-2025111675-A1 | Digestive system simulator apparatus for high-yield screening | Inactive | 27-Nov-2023 |
Nintx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nintx Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adeste AS | Corporation | Minority | ||
| Ecoa Capital | PE/Buyout | Minority | ||
| Angel (individual) | Minority | |||
| Laboratory Tiaraju | Corporation | Minority | ||
| MOV Investimentos | Impact Investing | Minority |
Nintx FAQs
-
When was Nintx founded?
Nintx was founded in 2021.
-
Where is Nintx headquartered?
Nintx is headquartered in Sao Paulo, Brazil.
-
What is the size of Nintx?
Nintx has 9 total employees.
-
What industry is Nintx in?
Nintx’s primary industry is Drug Discovery.
-
Is Nintx a private or public company?
Nintx is a Private company.
-
What is Nintx’s current revenue?
The current revenue for Nintx is .
-
How much funding has Nintx raised over time?
Nintx has raised $13M.
-
Who are Nintx’s investors?
Adeste AS, Ecoa Capital, , Laboratory Tiaraju, and MOV Investimentos are 5 of 10 investors who have invested in Nintx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
